Neuroblastoma – Pipeline Review, H2 2016
- Pages: 366
- Published: November 2016
- Report Code: GMDHC8722IDB
Global Markets Direct’s, ‘Neuroblastoma – Pipeline Review, H2 2016’, provides an overview of the Neuroblastoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects
The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Neuroblastoma
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Ability Pharmaceuticals SL
Acetylon Pharmaceuticals Inc
Advanced Accelerator Applications SA
Alissa Pharma
Ampio Pharmaceuticals Inc
APEIRON Biologics AG
AstraZeneca Plc
Bayer AG
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
BioLineRx Ltd
Bionucleon Srl
Biotec Pharmacon ASA
Cancer Prevention Pharmaceuticals, Inc.
Cebiotex SL
Celgene Corp
Cielo Therapeutics Inc
Cleveland BioLabs Inc
Codagenix, Inc.
CorMedix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
DEKK-TEC Inc
EnGeneIC Ltd
Errant Gene Therapeutics LLC
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Green Cross Cell Corp
Ignyta Inc
Incuron, LLC
Juno Therapeutics Inc
Kolltan Pharmaceuticals Inc
Lindis Biotech GmbH
MabVax Therapeutics Holdings Inc
MediaPharma srl
Merck & Co Inc
Merrimack Pharmaceuticals Inc
Morphogenesis Inc
Novartis AG
Novogen Ltd
OGD2 Pharma SAS
Pfizer Inc
Pharmacyclics Inc
Progenics Pharmaceuticals Inc
ProNAi Therapeutics Inc
Recombio SL
Ribomic Inc.
Sapience Therapeutics Inc
Sareum Holdings Plc
Shionogi & Co Ltd
Syros Pharmaceuticals Inc
Tiltan Pharma Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.